On Wednesday, Biogen made an important announcement about its Alzheimer’s program, the one that puts billions of dollars and millions of hopes on the line. But it didn’t arrive via press release, and it wasn’t detailed in a filing with the Securities and Exchange Commission. Instead it was spoken softly by Dr. Al Sandrock, Biogen’s chief medical officer, before an audience of investors in New York.

“We did see more variability on the primary endpoint than assumed when we did the initial sample size estimations,” Sandrock said of two trials on aducanumab, the company’s all-important Alzheimer’s therapy. “So we decided to increase the sample size to maintain 90 percent power.”

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy